In 2020, a study from South-East Germany failed to identify the germline presence of BRCA1 c.-107A > T SNV in a large population, including 3297 patients with a high familial risk to develop breast and ovarian cancer, without a germline BRCA1 or BRCA2 mutation. This evidence concerns the gene BRCA2 and ovarian cancer.